Company research
MEDICINOVA INC
CIK 1226616Updated Nov 13, 2026
SecurityMNOV · NASDAQ · equity
MNOV price & chart
Loading TradingView…
NASDAQ:MNOV on TradingView ↗About the company
We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (“U.S.”) market. Our current strategy is to focus our development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (“MS”), amyotrophic lateral sclerosis (“ALS”), chemotherapy-induced peripheral neuropathy (“CIPN”), degenerative cervical myelopathy (“DCM”), glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence), and prevention of acute respiratory distress syndrome (“ARDS”), and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (“NAFLD”), and hypertriglycedemia.
In the news
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) ↗
Seeking Alpha
At a glance: stocks gapping down premarket ↗
Beyond GLP-1 injectables, who wins the next phase for obesity drugs? ↗
SEC disclosures
MEDICINOVA INC files 8-K: Material Event ↗
Recent filings
10-Q filing
Entry into a Material Definitive Agreement
Items 1.01
Termination of a Material Definitive Agreement
Items 1.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 47,578,388Source | 58,119,421Source | 40,433,469Source | 49,823,875Source | 60,403,808Source | 42,704,854Source | 52,431,150Source | 62,893,917Source | 45,603,109Source | 55,875,926Source | 66,269,977Source | 74,154,905Source |
| Property, Plant and Equipment, NetUSD | 12,933Source | 30,813Source | 9,829Source | 15,361Source | 35,813Source | 14,878Source | 20,386Source | 40,384Source | 8,340Source | 25,507Source | 45,800Source | 45,269Source |
| GoodwillUSD | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 32,562,612Source | 42,280,618Source | 25,415,921Source | 34,259,637Source | 44,337,824Source | 27,329,415Source | 36,571,466Source | 47,138,799Source | 30,806,477Source | 40,359,738Source | 50,999,442Source | 18,505,493Source |
| Assets, CurrentUSD | 32,922,521Source | 43,265,478Source | 25,921,426Source | 35,123,834Source | 45,505,587Source | 28,146,059Source | 37,679,307Source | 47,863,595Source | 30,991,304Source | 41,074,279Source | 51,174,380Source | 58,987,109Source |
| Prepaid Expense and Other Assets, CurrentUSD | 359,909Source | 984,860Source | 505,505Source | 729,598Source | 1,167,763Source | 571,544Source | 1,107,841Source | 724,796Source | 184,827Source | 714,541Source | 174,938Source | 499,403Source |
| Operating Lease, Right-of-Use AssetUSD | 223,698Source | 403,894Source | 101,974Source | 265,444Source | 443,172Source | 143,677Source | 312,221Source | 519,307Source | 184,229Source | 356,904Source | 575,406Source | 629,495Source |
| Other Assets, NoncurrentUSD | 18,996Source | 18,996Source | 0Source | 18,996Source | 18,996Source | 0Source | 18,996Source | 70,391Source | 18,996Source | 18,996Source | 74,151Source | 92,792Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 3,613,632Source | 3,053,860Source | 3,162,867Source | 2,967,006Source | 2,998,654Source | 3,297,620Source | 2,500,674Source | 3,063,473Source | 4,016,428Source | 3,372,375Source | 3,891,553Source | 3,912,870Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 49,046Source | 49,046Source | 49,221Source | 49,046Source | 49,046Source | 49,221Source | 49,046Source | 49,046Source | 49,221Source | 49,046Source | 49,046Source | 49,046Source |
| Retained Earnings (Accumulated Deficit)USD | -435,946,920Source | -423,936,590Source | -443,649,596Source | -432,896,547Source | -421,084,411Source | -441,335,457Source | -429,615,362Source | -418,456,211Source | -438,749,199Source | -426,751,242Source | -415,701,693Source | -407,130,177Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -126,803Source | -123,803Source | -127,390Source | -127,371Source | -131,527Source | -128,130Source | -130,052Source | -126,982Source | -127,180Source | -135,154Source | -118,090Source | -115,285Source |
| Stockholders' Equity Attributable to ParentUSD | 43,964,756Source | 55,065,561Source | 37,270,602Source | 46,856,869Source | 57,405,154Source | 39,407,234Source | 49,930,476Source | 59,830,444Source | 41,586,681Source | 52,503,551Source | 62,378,424Source | 70,242,035Source |
| Additional Paid in Capital, Common StockUSD | 479,989,433Source | 479,076,908Source | 480,998,367Source | 479,831,741Source | 478,572,046Source | 480,821,600Source | 479,626,844Source | 478,364,591Source | 480,413,839Source | 479,340,901Source | 478,149,161Source | 477,438,451Source |
| Liabilities and EquityUSD | 47,578,388Source | 58,119,421Source | 40,433,469Source | 49,823,875Source | 60,403,808Source | 42,704,854Source | 52,431,150Source | 62,893,917Source | 45,603,109Source | 55,875,926Source | 66,269,977Source | 74,154,905Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,337,441Source | 2,596,918Source | 2,961,075Source | 2,648,176Source | 2,494,379Source | 3,095,828Source | 2,133,684Source | 2,510,496Source | 3,797,507Source | 2,959,123Source | 3,279,101Source | 3,187,459Source |
| Operating Lease, Liability, CurrentUSD | 180,751Source | 201,976Source | 117,038Source | 184,842Source | 190,047Source | 165,198Source | 189,860Source | 217,887Source | 194,331Source | 193,769Source | 215,926Source | 157,505Source |
| Accounts Payable, CurrentUSD | 745,958Source | 708,203Source | 950,503Source | 569,445Source | 667,695Source | 852,367Source | 718,891Source | 804,764Source | 624,995Source | 1,102,494Source | 1,003,937Source | 424,646Source |
| Operating Lease, Liability, NoncurrentUSD | 74,399Source | 255,150Source | 0Source | 117,038Source | 302,483Source | 0Source | 165,198Source | 351,185Source | 17,129Source | 211,460Source | 410,660Source | 523,619Source |
| Deferred Income Tax Liabilities, NetUSD | 201,792Source | 201,792Source | 201,792Source | 201,792Source | 201,792Source | 201,792Source | 201,792Source | 201,792Source | 201,792Source | 201,792Source | 201,792Source | 201,792Source |
| Other Liabilities, NoncurrentUSD | 74,399Source | 255,150Source | 0Source | 117,038Source | 302,483Source | 0Source | 165,198Source | 351,185Source | 17,129Source | 211,460Source | 410,660Source | 523,619Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 201,792Source | 201,792Source | 201,792Source | 201,792Source |
| Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | — | 39,982,213Source |
| Accounts Receivable, after Allowance for Credit Loss, Current | —Source | — | —Source | —Source | — | —Source | — | — | — | — | — | — |
| Deferred Revenue, Current | —Source | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -2,586,258Source | -2,864,120Source | -11,997,957Source | -11,049,549Source | -8,571,516Source | -14,069,083Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 4,260Source | 5,177Source | 20,099Source | 21,077Source | 20,295Source | 17,707Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 407,761Source | 285,943Source | 829,095Source | 1,191,740Source | 710,710Source | 642,522Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,470,213Source | -3,783,661Source | -9,810,061Source | -10,642,964Source | -7,431,038Source | -12,911,563Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -10,825Source | 0Source | -2,899Source | -697Source | 39,907,716Source | -40,005,010Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 10,825Source | 0Source | 2,899Source | 895Source | 21,299Source | 5,010Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 244,018Source | — | — | 7,920Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -3,477,062Source | -3,788,272Source | -9,553,261Source | -10,639,704Source | 32,493,949Source | -52,925,461Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 5,994Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 157,692Source | 504,862Source | 176,767Source | 204,897Source | 407,761Source | 285,943Source | 829,095Source | 1,191,740Source | 710,710Source | 642,522Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | -448,903Source | -122,475Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | 198Source | -472Source | — |
| General and Administrative ExpenseUSD | — | — | 1,806,070Source | 1,449,728Source | 1,829,784Source | 1,436,690Source | 1,590,175Source | 1,362,708Source | 6,159,205Source | 5,480,600Source | 5,242,370Source | 5,484,857Source |
| GoodwillUSD | — | — | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source | 9,600,240Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 5,994Source | 5,537Source | 3,047Source | 2,822Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,050,373Source | -2,852,179Source | -2,314,139Source | -3,281,185Source | -2,586,258Source | -2,864,120Source | -11,997,957Source | -11,049,549Source | -8,571,516Source | -14,069,083Source |
| Operating ExpensesUSD | — | — | 3,504,317Source | 3,309,128Source | 2,999,628Source | 3,741,691Source | 3,022,790Source | 3,202,510Source | 13,692,659Source | 12,675,331Source | 10,900,265Source | 14,628,649Source |
| Other Nonoperating Income (Expense)USD | — | — | -10,225Source | 9,102Source | -4,881Source | 952Source | -3,416Source | 2,279Source | -12,753Source | -39,485Source | -502,869Source | -247,285Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 244,018Source | — | — | — |
| Increase (Decrease) in Accounts Receivable | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 123,319Source | — | 458,439Source | 134,599Source | 186,984Source | — | 409,657Source | — | 1,000,000Source | — |
| Operating Income (Loss)USD | — | — | -3,380,998Source | -3,309,128Source | -2,541,189Source | -3,607,092Source | -2,835,806Source | -3,202,510Source | -13,283,002Source | -12,675,331Source | -9,900,265Source | -14,628,649Source |
| Other Nonoperating Income (Expense)USD | — | — | -10,225Source | 9,102Source | -4,881Source | 952Source | -3,416Source | 2,279Source | -12,753Source | -39,485Source | -502,869Source | -247,285Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -11,991,963Source | -11,044,012Source | -8,568,469Source | -14,066,261Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 5,994Source | 5,537Source | 3,047Source | 2,822Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,050,373Source | -2,852,179Source | -2,314,139Source | -3,281,185Source | -2,586,258Source | -2,864,120Source | -11,997,957Source | -11,049,549Source | -8,571,516Source | -14,069,083Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.06Source | -0.06Source | -0.05Source | -0.07Source | -0.05Source | -0.06Source | -0.24Source | -0.23Source | -0.17Source | -0.29Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.06Source | -0.06Source | -0.05Source | -0.07Source | -0.05Source | -0.06Source | -0.24Source | -0.23Source | -0.17Source | -0.29Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 49,046,246Source | 49,046,246Source | 49,221,246Source | 49,046,246Source | 49,221,246Source | 49,046,246Source | 49,063,438Source | 49,046,246Source | 49,046,246Source | 49,045,342Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 49,046,246Source | 49,046,246Source | 49,221,246Source | 49,046,246Source | 49,221,246Source | 49,046,246Source | 49,063,438Source | 49,046,246Source | 49,046,246Source | 49,045,342Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 5,994Source | 5,537Source | 3,047Source | 2,822Source |
| General and Administrative ExpenseUSD | — | — | 1,806,070Source | 1,449,728Source | 1,829,784Source | 1,436,690Source | 1,590,175Source | 1,362,708Source | 6,159,205Source | 5,480,600Source | 5,242,370Source | 5,484,857Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -12,004,784Source | -11,060,506Source | -8,587,967Source | -14,084,240Source |
| Interest Income, OtherUSD | — | — | 340,850Source | 447,847Source | 231,931Source | 324,955Source | 252,964Source | 336,111Source | 1,303,792Source | 1,670,804Source | 1,834,665Source | 809,673Source |
| Operating ExpensesUSD | — | — | 3,504,317Source | 3,309,128Source | 2,999,628Source | 3,741,691Source | 3,022,790Source | 3,202,510Source | 13,692,659Source | 12,675,331Source | 10,900,265Source | 14,628,649Source |
| Research and Development ExpenseUSD | — | — | 1,500,000Source | 1,800,000Source | 900,000Source | 2,000,000Source | 1,200,000Source | 1,700,000Source | 6,700,000Source | 6,800,000Source | 5,300,000Source | 8,700,000Source |
| Selling ExpenseUSD | — | — | 115,272Source | — | 140,680Source | 116,349Source | 170,101Source | — | 378,606Source | — | — | — |
Offerings
Registration 333-289801
Filing attachments
d101814dex991.htm · 8-K · 2026-02-20
EX-99.1 2 d101814dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 February 20, 2026 Unaudited Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 (Under U.S. GAAP) Company name: Medicinova, Inc. Listing: Tokyo Stock Exchange Securities code: 4875 URL: h…
Read attachment ↗d940973dex991.htm · 8-K · 2025-03-11
EX-99.1 2 d940973dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 MediciNova Corporate Presentation March 2025 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding MediciNova’s clinical trials supporting the safety and efficacy of its product candidates and…
Read attachment ↗